Journal of Clinical Endocrinology & Metabolism, Vol 80, 2069-2076, Copyright © 1995 by Endocrine Society

ARTICLES

The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis

H de Boer, GJ Blok, B Voerman, P de Vries, C Popp-Snijders and E van der Veen
Department of Endocrinology, Free University Hospital, Amsterdam, The Netherlands.

The prevalence of clinical signs and symptoms related to fluid retention is high in most studies evaluating the efficacy of GH treatment in GH-deficient (GHD) adults. This may be a consequence of supraphysiological GH replacement. To examine whether fluid retention is a dose-related phenomenon, we evaluated the impact of various GH substitution doses on body fluid status in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled study. The patients were randomized to receive either placebo (n = 13) or GH in a dose of 1 (n = 11), 2 (n = 10), or 3 (n = 12) IU/m2.day, respectively. Treatment was started at one third of the predetermined dose and was subsequently increased by another third every month until the maintenance dose was reached. Tissue hydration was assessed by means of electrical impedance measurements. Normal values were obtained from 128 age- and sex-matched controls. In the untreated GHD state, whole body resistance was abnormally high (observed, 642 +/- 82 omega; predicted, 550 +/- 31 omega; P < 0.001). This was mainly caused by an increase in specific resistance of the lean body as a consequence of a reduction in extracellular water (ECW). The first month of GH treatment was associated with a sharp decline in electrical resistance that was attributed to an increase in ECW. Whole body resistance reached its nadir after 3 months of treatment (517 +/- 72 omega, i.e. 19.6 +/- 6.5% lower than before treatment; P < 0.001) and did not change significantly thereafter. The GH-induced changes in body resistance were dose dependent. A significant decrease was observed with a dose as low as 0.33 IU/m2.day (P < 0.005). However, whole body resistance remained higher than normal in patients receiving less than 0.67 IU/m2.day (P = 0.05). Abnormally low resistance values, indicative of overhydration, were observed in patients receiving doses equal to or higher than 2 IU/m2.day (P < 0.005). Regression analysis of the pooled data showed that GH replacement in a dose of 1.10 IU/m2.day (95% confidence interval, 0.85-1.45 IU/m2.day) resulted in a normalization of whole body resistance. In conclusion, GH replacement therapy in adults rapidly corrects the preexisting deficit in ECW. This rehydration process is dose dependent and may result in a substantial weight gain.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				D Maiter, R Abs, G Johannsson, M Scanlon, P J Jonsson, P Wilton, and M Koltowska-Haggstrom Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur. J. Endocrinol., August 1, 2006; 155(2): 253 - 260. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				A. R. Hoffman, C. J. Strasburger, A. Zagar, W. F. Blum, A. Kehely, and M. L. Hartman Efficacy and Tolerability of an Individualized Dosing Regimen for Adult Growth Hormone Replacement Therapy in Comparison with Fixed Body Weight-Based Dosing J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3224 - 3233. [Abstract] [Full Text] [PDF]

				D. M. Cook, B. M. K. Biller, M. L. Vance, A. R. Hoffman, L. S. Phillips, K. M. Ford, D. P. Benziger, A. Illeperuma, S. L. Blethen, K. M. Attie, et al. The Pharmacokinetic and Pharmacodynamic Characteristics of a Long-Acting Growth Hormone (GH) Preparation (Nutropin Depot) in GH-Deficient Adults J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4508 - 4514. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				B.-A. Bengtsson and G. Johannsson The Treatment of Growth Hormone Deficiency in Adults J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 933 - 937. [Full Text]

				J. C. ter Maaten, H. de Boer, O. Kamp, L. Stuurman, and E. A. van der Veen Long-Term Effects of Growth Hormone (GH) Replacement in Men with Childhood-Onset GH Deficiency J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2373 - 2380. [Abstract] [Full Text]

				M. W. Haymond Nutritional and Metabolic Endpoints J. Nutr., January 1, 1999; 129(1): 273S - 273S. [Abstract] [Full Text] [PDF]

				W. M. Drake, D. Coyte, C. Camacho-Hübner, N. M. Jivanji, G. Kaltsas, D. F. Wood, P. J. Trainer, A. B. Grossman, G. M. Besser, and J. P. Monson Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3913 - 3919. [Abstract] [Full Text]

				P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]

				H. de Boer and E. A. van der Veen Why Retest Young Adults with Childhood-Onset Growth Hormone Deficiency? J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2032 - 2036. [Full Text] [PDF]

				N. Bravenboer, P. Holzmann, H. de Boer, J. C. Roos, E. A. van der Veen, and P. Lips The Effect of Growth Hormone (GH) on Histomorphometric Indices of Bone Structure and Bone Turnover in GH-Deficient Men J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1818 - 1822. [Abstract] [Full Text] [PDF]

				P. Burman, A. G. Johansson, A. Siegbahn, B. Vessby, and F. A. Karlsson Growth Hormone (GH)-Deficient Men Are More Responsive to GH Replacement Therapy Than Women J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 550 - 555. [Abstract] [Full Text] [PDF]

				Y. J. H. Janssen, M. Frolich, and F. Roelfsema A Low Starting Dose of Genotropin in Growth Hormone-Deficient Adults J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 129 - 135. [Abstract] [Full Text] [PDF]